Product Images Sunitinib Malate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Sunitinib Malate NDC 0093-8229 by Teva Pharmaceuticals Usa, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

1 - image 1

1 - image 1

1 - image 2

1 - image 2

1 - image 3

1 - image 3

The given text shows the results of two treatments Sunitinib Malate and IFN-a on 375 subjects. Sunitinib Malate shows a median of 47.3 weeks of treatment whereas IFN-a shows a median of 22.0 weeks. The Hazard Ratio calculated is 0.42 with a 95% CI (0.32, 0.54). Based on the Progression-Free Survival Probability, Sunitinib Malate shows better results. However, it is important to note that there might have been a significant difference in the treatment methods or processes, which can affect the validity of direct comparison between these treatments.*

1 - image 4

1 - image 4

This text provides data on disease-free survival probability over 6.8 years for a group of 309 subjects treated with Sunitinib malate and a group of 306 subjects treated with a placebo. The hazard ratio between the two groups is 0.76 with a 95% confidence interval of 0.59 to 0.98 and a p-value of 0.03. A graph shows the probability of disease-free survival over time.*

1 - image 5

1 - image 5

This text presents data on the Progression-Free Survival Probability (%) for individuals that received Sunitinib Malate compared to those that received a placebo. The hazard ratio was 0.427, indicating that individuals who received Sunitinib Malate had a significantly lower risk of progression than those who received placebo. The median progression-free survival time for Sunitinib Malate was 10.2 months, whereas the median time for placebo was 5.4 months. The 95% confidence interval for the hazard ratio was 0.271-0.673, and the p-value was 0.0000146. The text also includes a figure showing the percentage of subjects remaining progression-free over time for each treatment group.*

1 - image 6

1 - image 6

This is a medication label for Sunitinib Malate Vsl with a dosage of 12.5mg per capsule. The capsules need to be stored at a temperature range of 68-77°F, and should be kept out of reach of children. The manufacturer of the medication is B. The label includes the NDC number, dosage information, and manufacturing details.*

1 - image 7

1 - image 7

1 - image 8

1 - image 8

1 - image 9

1 - image 9

This is a medication called Sunitinib Malate, which comes in capsule form. The usual dosage for this medication can be found in the accompanying prescribing information. It should be stored between 20°C to 25°C and dispensed in a tightly sealed container, and kept out of reach of children. The manufacturer is Teva Pharmaceuticals USA, Inc. The text includes a prescription number, lot number, and other important information for pharmacists.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.